Latest news with #CapEx
CNBC
a day ago
- Business
- CNBC
Crowdell: The outlook for utilities has never looked better
Anthony Crowdell, Senior Analyst at Mizuho Americas, says utilities are thriving with rising CapEx, data center demand, and possible Fed rate cuts, while still offering defensive value and strong earnings.
New York Post
3 days ago
- Business
- New York Post
Texas Instruments to spend $60B to boost US chip manufacturing under Trump push
Texas Instruments said Wednesday it will spend more than $60 billion to expand its US manufacturing footprint, the latest chipmaker to ramp up domestic production amid pressure from the Trump administration to reshore the semiconductor supply chain. In December, the Biden administration finalized a $1.61 billion government subsidy for Texas Instruments to support construction of three new facilities after the company announced plans to invest at least $18 billion under the $52.7 billion CHIPS and Science bill. The company said Wednesday the $60 billion will be used to build or expand seven chip-making facilities at three sites in Texas and Utah, including two new facilities in Sherman, Texas, and will create 60,000 jobs, calling it the 'largest investment in foundational semiconductor manufacturing in US history.' Texas Instruments said the $60 billion investment will create 60,000 jobs and called it the 'largest investment in foundational semiconductor manufacturing in US history.' REUTERS In August 2024, the company said it could build seven chip-building facilities and spend up to $40 billion on its Sherman, Texas operations and $21 billion on Utah and other Texas plants. Texas Instruments has been building facilities in Texas and one in Utah as part of efforts to boost in-house manufacturing and stave off rising competition from Chinese analog chipmakers. The company did not give a precise timeline for the investment, which includes up to $46 billion in Texas and about $15 billion in Utah. Texas Instruments said its long-term CapEx plan is unchanged. Unlike AI chip firms Nvidia and AMD, TI makes analog or foundational chips used in everyday devices such as smartphones, cars and medical devices, giving it a large client base that includes Apple, SpaceX and Ford Motor. The spending plan follows similar announcements from others in the semiconductor industry, including Micron, which said last week that it will expand its US investment by $30 billion, taking its planned spending to $200 billion. Texas Instruments has been building facilities in Texas and one in Utah as part of efforts to boost in-house manufacturing and stave off rising competition from Chinese analog chipmakers. REUTERS Analysts have said they see the spending plans as overtures to President Trump, who has repeatedly threatened to kill the $52.7 billion 2022 CHIPS and Science Act and warned of potential new tariffs on semiconductor imports. Commerce Secretary Howard Lutnick said on Wednesday the Texas Instruments investment will boost 'foundational semiconductors that go into the electronics that people use every day. Our partnership with TI will support US chip manufacturing for decades to come.' Like other companies unveiling such spending commitments, TI's announcement includes funds already allocated to facilities that are either under construction or ramping up.
CNBC
4 days ago
- Business
- CNBC
Rare earth deal with China is 'long-term' industrial crisis, says MP Materials CEO
James Litinsky, MP Materials CEO, joins 'Closing Bell Overtime' to talk rare earth deal with China, its supply chain, CapEx plans, and more.
Yahoo
13-06-2025
- Business
- Yahoo
Kofola CeskoSlovensko AS (XPRA:KOFOL) Q1 2025 Earnings Call Highlights: Innovations and ...
Release Date: June 11, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Kofola CeskoSlovensko AS (XPRA:KOFOL) successfully launched key innovations such as Targa Florio retail and replaced their route portfolio. The company is well-prepared for the top season and maintains its EBITDA target for 2025. Export markets showed resilience with a sales growth of 4% compared to the same period last year. Kofola CeskoSlovensko AS (XPRA:KOFOL) modernized the can filling line at the production plant in Aency, enhancing production efficiency. The company implemented a sustainable delivery solution using electric trucks, demonstrating a commitment to reducing its environmental footprint. Kofola CeskoSlovensko AS (XPRA:KOFOL) reported a decline in results compared to the first quarter of 2024, with EBITDA decreasing by approximately 100 million Czech crowns. The sugar tax imposed in Slovakia significantly impacted results, contributing to half of the EBITDA decrease. Adverse weather conditions, including a cold and rainy spring, negatively affected consumer sentiment and sales. Higher VAT on sugar and non-alcoholic beverages in Slovenia and a higher returnable packaging fee in Croatia led to increased consumer prices and lower sales volumes. The company faced a consumer boycott in Croatia, further influencing lower sales volumes. Warning! GuruFocus has detected 8 Warning Signs with XPRA:KOFOL. Q: I was surprised by the decline in your gross margin despite favorable commodity developments. Could you elaborate on this and the higher marketing costs in Q1? What revenue impact do you expect from these costs in the second half of the year? A: The decline in gross profit margin is due to fixed costs not being covered because of lower volumes. There were no pricing pressures; it was purely a function of missing revenues. Regarding marketing costs, we maintain expenses at about 5-5.5% of revenues. The timing of these expenses is different this year, as we started campaigns earlier to ensure consumer awareness of new products. We believe the guidance is achievable, but a strong summer is crucial. Q: Despite indications of decreasing volumes and value, there was positive revenue development in Q1. What is the main reason for this difference? A: The main reason is the inclusion of breweries in our consolidated numbers from mid-March 2024. This accounts for 2.5 months of beer sales in our P&L for 2025, leading to growing revenues despite lower sales volumes compared to the prior year. Q: Did you acquire a 100% share in the Panama coffee farm, and what are your plans for it? A: Yes, we acquired a 100% share in the farm. It spans approximately 45 hectares and produces specialty coffee. All production will be taken over by Laros and distributed in the Czech and Slovak markets. Q: What is the CapEx development in Q1, and does it include M&A costs? A: Q1 is typically more CapEx intensive. We spent approximately 240 million Czech crowns, about one-quarter of our full-year guidance. This does not include M&A costs, which are separate from CapEx. Q: Can you elaborate on the acquisition of Krondorf? A: We acquired Krondorf's assets, including water sources and land, to operate more independently at our Koroni production plant. This acquisition was based on asset value rather than business value, allowing us to streamline operations and potentially resume Krondorf mineral water production in the future. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
12-06-2025
- Business
- Yahoo
Moderna explores outside financing for vaccine trials, shares dip
-- Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) shares fell 2.2% Thursday as the company confirmed it is seeking outside investment to support its late-stage vaccine programs. The move underscores the biotech firm's effort to align capital efficiency with strategic advancement across its product pipeline amid slowing COVID-19 revenue. 'We are very actively talking to potential partners right now,' CEO Stéphane Bancel said Wednesday at the Goldman Sachs Annual Global Healthcare Conference. He added that the discussions involved both pharmaceutical companies and financial partners, enabling the company to progress stalled late-stage candidates while controlling costs. A key focus for potential funding includes its latent virus vaccine programs, such as those targeting Epstein-Barr virus (EBV), herpes simplex virus (HSV), and varicella-zoster virus (VZV). 'We are working actively with [a] pharma company on the one hand and [a] financial partner on the other hand because we want those products to get to phase three,' Bancel said. Moderna has paused internal spending for those programs, opting instead to secure external capital and avoid further capital expenditure. 'We could launch EBV without adding $1 of CapEx. We could launch HSV without adding $1 of CapEx,' Bancel said, noting that Moderna's existing facilities have sufficient capacity to support production without the need for additional investment. The company's earlier collaboration with Blackstone (NYSE:BX) on financing a flu vaccine program stands as a precedent for these new deal structures. 'We would rather wait a few months to get the best partnership than being in a hurry and destroy value for shareholders by being in a hurry,' Bancel noted. While the company has over $8.5 billion in cash on hand, Bancel indicated this financing effort is about maximizing efficiency, not bridging funding gaps. 'We want to figure out who is the best partner in terms of capabilities and in terms of value,' he said, reiterating that securing the right structure is more important than speed. The funding push comes as Moderna aims to return to profitability by 2028 while ramping its oncology and respiratory portfolios. Shares finished the day down 2.2%, reflecting cautious sentiment amid uncertainty around vaccine uptake, trial timelines, and partnering outcomes. Related articles Moderna explores outside financing for vaccine trials, shares dip Israel considers military action against Iran, sources tell ABC News Micron boosts planned U.S. investment by $30 billion amid AI-driven demand Sign in to access your portfolio
